We are delighted to announce the publication of the SBRI Healthcare Annual Review 2020-22.
The programme continues to go from strength to strength, signalling the diverse challenges the NHS and wider health and social care system face, and inviting outstanding entrepreneurs to put forward breakthrough innovations that can deliver improved outcomes of care.
In the financial years 2020-22, SBRI Healthcare, funded by the Accelerated Access Collaborative, awarded £17m of funding to 56 high-potential healthcare innovations across areas including Urgent & Emergency Care, Integrated Care & Social Care, Mental Health Inequalities in Children & Young People and NHS Reset & Recovery.
We secured co-funding opportunities from charity partners including the Stroke Assocation, and successfully piloted a bespoke competition, the first of its kind, to generate evidence in real-world settings.
We continued to provide enhanced support for innovators through our Investment Readiness Programme, Showcase event, webinar series' on the regulatory landscape, roadmap to the NHS, health economics, use of the NICE Meta Tool and the Women in HealthTech Innovation Leadership programme.
2020-2022 also saw us scale the programme into new areas. We joined forces with the NHS Cancer Programme at NHS England to launch the Innovation Open call, supporting the implementation of innovations tackling the early diagnosis of cancer, and launched a new competition with the Greener NHS team to support innovations that help the NHS achieve its Net Zero targets, whilst improving patient care.
The Annual Review features eight new case studies of innovators, demonstrating the real-world impact on patients and NHS efficiency improvements, and showcasing the value the programme adds to companies' growth and wealth creation in the UK and overseas, leveraging of private investment.
SBRI Healthcare in numbers -- Impact to April 2022
- £102 million total invested
- 265 innovations supported
- £600 million private investment leveraged
- 162 IP achieved
- >7.2m patients involved through sales and trials
- 936 New collaborations established
- 47 products exported
- 81 companies with commercial revenues
- 3 acquisitions
- 1 IPO
- 18,810 Sites accessed through trials of sales
- 1,776 jobs created/retained
- 67 companies with sales in the NHS
Explore the Annual Review 2020-22 here.